SOHO 2022 Tenth Annual Meeting

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

SOHO 2022 Tenth Annual Meeting

Myeloma
Lymphoma
Leukemia
MDS and MPN
Benign Hematology
Event

Playback speed

10 seconds

SOHO 2022: Characteristics of Patients With Myelofibrosis Taking Ruxolitinib for 3 or More Years

By SOHO 2022 Tenth Annual Meeting FEATURING Lucia Masarova

0 views

October 24, 2022

Comments 0

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

Leukemia

06:06

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Characteristics of Patients With Myelofibrosis Taking Rux…

Feat. L. Masarova

16:50

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Role of ddPCR in CML Today

Feat. J. Radich, S. Soverini

15:48

SOHO 2022 Tenth Annual Meeting

SOHO 2022: State of the Art in CML

Feat. M. Deininger, G. Saglio

08:51

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Long-Term Outcomes After Haplo-SCT for Hematologic Malign…

Feat. S. Saengboon

09:22

SOHO 2022 Tenth Annual Meeting

GLOW Study - First Prospective Data on MRD Outcomes After Fixed-Dura…

Feat. C. Owen

09:54

SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: CML

Feat. T. Hughes

08:27

SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: CLL

Feat. F. Cymbalista

12:33

SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: AML

Feat. H. Kantarjian

10:33

Lori Muffly

Next Questions: ALL

11:20

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Orca-T Results in High GVHD-Free and Relapse-Free Surviva…

Feat. S. Srour

15:25

SOHO 2022 Tenth Annual Meeting

Supportive Therapy in CLL

Feat. C. Sun

14:10

SOHO 2022 Tenth Annual Meeting

CLL - Real World Data With Small Molecules

Feat. F. Cymbalista

14:13

SOHO 2022 Tenth Annual Meeting

CLL DEBATE: How Many Drugs Are Needed in 1L CLL?

Feat. A. Mato

15:03

SOHO 2022 Tenth Annual Meeting

CLL DEBATE: Combination Small Molecules vs. Sequencing in CLL - Pro …

Feat. J. Brown

13:53

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Covalent BTK Inhibitors - How Do They Compare in CLL?

Feat. J. Byrd

15:10

SOHO 2022 Tenth Annual Meeting

Clinical Significance of B-Cell Receptor Stereotypy in CLL

Feat. K. Stamatopoulos

10:34

SOHO 2022 Tenth Annual Meeting

SOHO 2022: PACE and OPTIC Trials - Dose Modification Dynamics of Pon…

Feat. H. Kantarjian

16:33

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Asciminib or Ponatinib for Multiresistant CML Patients?

Feat. J. Cortés

14:57

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Immunotherapy - The Way Forward to Maximize TFR in CML?

Feat. D. Rea

13:34

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Beyond TKI Therapy in CML

Feat. M. Copland

09:52

SOHO 2022 Tenth Annual Meeting

SOHO 2022: AGILE - A Phase 3, Global, Randomized, Double-Blind Study…

Feat. A. de la Fuente, C. DiNardo

16:04

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Emerging CAR T-Cell Therapy Approaches in AML

Feat. S. Kenderian

15:39

SOHO 2022 Tenth Annual Meeting

SOHO 2022 AML DEBATE: Is MRD More Prognostic Than Initial Presentati…

Feat. C. Lindsley

16:37

SOHO 2022 Tenth Annual Meeting

SOHO 2022 AML DEBATE: Is MRD More Prognostic Than Initial Presentati…

Feat. M. Heuser

14:41

Farhad Ravandi

Is the Future of AML Therapy All Oral?

14:50

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Non-Intensive Treatment of Elderly/Unfit Patients With AML

Feat. T. Kadia

15:45

SOHO 2022 Tenth Annual Meeting

SOHO 2022: How Do We Overcome Resistance to Venetoclax in AML

Feat. M. Konopleva

15:21

SOHO 2022 Tenth Annual Meeting

SOHO 2022: FLT3-Mutated AML - Triplet vs. Doublet Therapy

Feat. E. Wang

15:13

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Menin Inhibitors in AML

Feat. E. Stein

17:07

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Novel Chemotherapy Can Eliminate the Need for Transplant …

Feat. N. Short

11:49

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Certain Patients With ALL Still Need a Transplant

Feat. J. Ribera, P. Scheinberg

15:52

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Approach to ALL in the Elderly

Feat. M. Luskin

13:46

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Management of Ph+ ALL in 2022

Feat. E. Jabbour

06:35

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Phase II Study of Blinatumomab in Combination With Ponati…

Feat. F. Haddad

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Dual Targeted CAR T-Cells for ALL

Feat. N. Frey

12:49

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Approach to Ph-Like ALL

Feat. E. Curran

16:13

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Blinatumomab in Pediatric ALL

Feat. S. Cooper

12:06

Catherine Coombs

New BTKi in CLL

09:23

SOHO 2022 Tenth Annual Meeting

Novel Agents in CLL

Feat. A. Danilov

11:07

SOHO 2022 Tenth Annual Meeting

SOHO 2022: BCL2i in CLL

Feat. A. Chanan-Khan

08:48

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Childhood CML

Feat. F. Millot

20:12

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Assessment and Management of TKI-Related AOEs in CML

Feat. G. Saglio

13:09

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Non BCR-ABL Mutations in CML - Do They Matter?

Feat. S. Soverini

15:43

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Advances in ALL Diagnosis and Treatment - The NOPHO Exper…

Feat. K. Schmiegelow

09:08

Selina Luger

Approaches to and Use of MRD in ALL

11:13

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Allogeneic CAR T-Cells in ALL

Feat. N. Jain

12:26

SOHO 2022 Tenth Annual Meeting

SOHO 2022: Is TP53-Mutated AML the Same Disease as TP53-Mutated MDS?

Feat. P. Valk

19:33

SOHO 2022 Tenth Annual Meeting

SOHO 2022 Update on CD47 Targeting Antibodies

Feat. N. Daver

20:35

SOHO 2022 Tenth Annual Meeting

SOHO 2022: What Is the Best Strategy for Therapy-Related AML?

Feat. P. Desai